Access cutting-edge gastroesophageal adenocarcinoma treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Pittsburgh location
Access gastroesophageal adenocarcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related gastroesophageal adenocarcinoma treatment provided free
Check if you qualify for this gastroesophageal adenocarcinoma clinical trial in Pittsburgh, PA
No-Cost Study Care
Local to Pittsburgh
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase.
Sponsor: Merck Sharp & Dohme LLC
Yes, this clinical trial (NCT06469944) has an active research site in Pittsburgh, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for gastroesophageal adenocarcinoma treatment options in Pittsburgh, PA, this clinical trial (NCT06469944) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastroesophageal adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all gastroesophageal adenocarcinoma clinical trials near you to find additional studies recruiting in your area.
See all esophageal cancer clinical trials recruiting in Pittsburgh — not just this study.
Browse Esophageal Cancer Trials in Pittsburgh →